M&A activity and investor cash expected to re-invigorate pharma and biotech in 2018

6 Dec 2017

Public and private investors look set to remain supportive of innovative, early-stage drug developers.

The upward momentum seen in the pharma and biotech sectors during 2017 looks set to continue into 2018, with more novel medicines due to hit the market and investor support for the industry remaining strong. According to EP Vantage, the current business-friendly stance at the FDA is unlikely to change next year, and M&A could see an uptick, driven by Big Pharma and big biotech’s need to re-stock pipelines and US tax reforms.

M&A activity and investor cash expected to re-invigorate pharma and biotech in 2018

The coming year will also test the commercial expectations that have been hung on novel therapies such as CAR-T and gene therapy, which are being launched into increasingly cost-sensitive markets. Important clinical read-outs from the field of immuno-oncology, where asset values remain very high, will be closely watched - all of which will help set the tone for investors throughout the year.

“Venture capital funds are very well stocked going into 2018, and both public and private investors look set to remain supportive of innovative, early-stage drug developers,” says Amy Brown, report author. “However there is evidence that expectations have got ahead of themselves in certain areas – particularly in immuno-oncology. To keep investors on side next year the industry needs to deliver some big pipeline wins, and important new drug launches need to perform.”

“Pharma & Biotech 2018 Preview”- Analysis Highlights:

  • Gilead’s new HIV triplet is the biggest potential new drug launch of 2018, with 2022 sales seen reaching $5bn
  • Abbvie’s Humira will be biggest selling drug in 2018, with global sales topping $20bn
  • Merck’s Keytruda will add the most new sales next year, $2.3bn
  • M&A activity expected to climb after slow 2017 – US tax reform could be a deciding factor for big deals
  • Another big year predicted for venture financing, as crossover funds return and push 2017 towards a record
  • IPO window expected to remain open to cashed-up private companies
  • Another strong year expected for licensing transactions in 2018, with a pick-up in activity in 2017 set to continue
  • Focus on immuno-oncology set to continue with new checkpoint targets moving through the clinic
  • Drug pricing debate in US expected to ease, but keep an eye on the states
  • Read More

    Related tags

    Market News

    Related news

    Spanish CDMO working ahead of EU serialisation deadline

    Spanish CDMO working ahead of EU serialisation deadline

    6 Dec 2018

    Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

    Read more 
    Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

    Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

    5 Dec 2018

    The financing will power the global commercial launch of the company's Fluidity One system.

    Read more 
    OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

    OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

    4 Dec 2018

    The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

    Read more 
    India to have strongest global growth in 2019?

    India to have strongest global growth in 2019?

    4 Dec 2018

    Main drivers cited as ‘high-growth domestic market’ and ‘expanding manufacturing exports’.

    Read more 
    Catalent to expand biologics packaging capabilities

    Catalent to expand biologics packaging capabilities

    3 Dec 2018

    Company's $14 million investment follows twentieth commercial drug approval at Bloomington, Indiana site.

    Read more 
    Merck successfully divests Consumer Health

    Merck successfully divests Consumer Health

    2 Dec 2018

    Closing of sale to Procter & Gamble at a cash purchase price of €3.4 billion completed.

    Read more 
    Digital manufacturing is a top priority for life sciences

    Digital manufacturing is a top priority for life sciences

    29 Nov 2018

    Zenith Technology survey reveals that more than half of those surveyed believe that Industry 4.0 will drive the most change.

    Read more 
    NIH to evaluate effectiveness of male contraceptive skin gel

    NIH to evaluate effectiveness of male contraceptive skin gel

    28 Nov 2018

    The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.

    Read more 
    QPS expands US-based Phase I clinical trial capabilities

    QPS expands US-based Phase I clinical trial capabilities

    27 Nov 2018

    Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.

    Read more 
    Hikma announces injectable licensing agreement

    Hikma announces injectable licensing agreement

    27 Nov 2018

    Company provided with exclusive rights to market a suite of Hansoh's injectable oncology medicines within the US for the next 5 years.

    Read more